Klinische Studie

Prospektives Akademisches Translationales Forschungsnetzwerk zur Optimierung der Onkologischen Versorgungsqualität in der Adjuvanten und Fortgeschrittenen/Metastasierten Situation: Versorgungsforschung, Pharmakogenomik, Biomarker, Pharmakoökonomie (PRAEGNANT).(PRAEGNANT)PROSPECT TRANSLAT RESEARCH NETWORK FOR OPTIMIZATION OF THE ONCOL HEALTH CARE QUALITY IN DJUVANT AND ADVANCED/METASTATIC SETTING: HEALTH CARE RESEARCH, PHARMACOGENOMICS, BIOMARKERS, HEALTH ECONOMICS
Krankheitsentität(en) Brust
StudientypInterventionsstudie
Wesentliche EinschlusskriterienEBC: • Adult breast cancer patients (age ≥18 years) • Patients with breast cancer and no evidence of distant metastases with a diagnosis not longer than 91 days before study entry. • Patients, who are able and willing to sign the informed consent form MBC: • Adult breast cancer patients (age ≥18 years) • Patients with the diagnosis of invasive breast cancer (irrespective of status of BC, e.g. TNM, receptor status etc.) • Patients, who are able and willing to sign the informed consent form • Patients with metastatic or locally advanced disease proven by clinical measures (i.e. standard imaging).
Wesentliche Ausschlusskriterien• Patients who did not sign the informed consent form • Patients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician
Statusrekrutierend
Ansprechpartner & KontaktCaritas-Krankenhaus St. Josef RegensburgFrauenheilkunde und Geburtshilfe Krankenhaus St JosefStudienzentrale0941 7823403fhk-studienzentrum(at)csj.de
zurück